Status epilepticus associated with the combination of valproic acid and clomipramine

被引:25
作者
DeToledo, JC [1 ]
Haddad, H [1 ]
Ramsay, RE [1 ]
机构
[1] FAIRVIEW TRAINING CTR,SALEM,OR
关键词
valproic acid; chlorimipramine; metabolism; seizures; status epilepticus;
D O I
10.1097/00007691-199702000-00012
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
An epileptic patient well controlled on valproic acid (VPA) developed a prolonged episode of status epilepticus 12 days after initiation of 75 mg of clomipramine (CMI) to treat depression. Serum level of VPA in the emergency room was unchanged from her previous levels; serum level of CMI was very elevated despite the relatively small dose of CMI. A pharmacokinetic interaction between VPA, an enzyme inhibitor, and CMI has,or been described but seemed to have occurred in this patient. Decreased metabolism of CMI Ed its metabolites, increased free CMI fraction, and precipitation of a nonlinear saturation kinetic stare has been described when CMI was used concomitantly with other highly protein-bound, enzyme inhibiting compounds. This case provides reasonable evidence that the combination of VPA and CMI may result in elevation of levels of CMI and possibly of its metabolites and may precipitate seizures in patients with an underlying predisposition. The elevated serum level of CMI at the time of the seizures, despite the relatively small oral dose of the drug, suggests that VPA may have inhibited its metabolism and/or elimination.
引用
收藏
页码:71 / 73
页数:3
相关论文
共 15 条
[1]   CLINICAL PHARMACOKINETICS OF CLOMIPRAMINE [J].
BALANTGORGIA, AE ;
GEXFABRY, M ;
BALANT, LP .
CLINICAL PHARMACOKINETICS, 1991, 20 (06) :447-462
[2]   PERSISTENT IMPAIRMENT OF CLOMIPRAMINE DEMETHYLATION IN RECENTLY DETOXIFIED ALCOHOLIC PATIENTS [J].
BALANTGORGIA, AE ;
GAY, M ;
GEXFABRY, M ;
BALANT, LP .
THERAPEUTIC DRUG MONITORING, 1992, 14 (02) :119-124
[3]   HIGH PLASMA-CONCENTRATIONS OF DESMETHYLCLOMIPRAMINE AFTER CHRONIC ADMINISTRATION OF CLOMIPRAMINE TO A POOR METABOLIZER [J].
BALANTGORGIA, AE ;
BALANT, L ;
ZYSSET, T .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 32 (01) :101-102
[4]  
BERTSCHY G, 1990, Encephale, V16, P43
[5]  
BETTS TA, 1968, LANCET, V1, P390
[6]  
BETTS TA, 1981, EPILEPSY PSYCHIATRY, P60
[7]  
Escande M, 1976, Encephale, V2, P133
[8]   MECHANISM OF VALPROATE-PHENOBARBITAL INTERACTION IN EPILEPTIC PATIENTS [J].
KAPETANOVIC, IM ;
KUPFERBERG, HJ ;
PORTER, RJ ;
THEODORE, W ;
SCHULMAN, E ;
PENRY, JK .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1981, 29 (04) :480-486
[9]  
KILLOH LG, 1961, ELECTROENCEPHALOGR C, V13, P216
[10]  
KOELLA WP, 1979, BIOL PSYCHIAT, V14, P485